Prof Jennifer Brown is Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, Massachusetts, US. She is also the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.
Prof Brown's interests include the development of novel targeted therapeutics for CLL, as well as CLL genomics. She has played a key role in the clinical development of idelalisib, ibrutinib and zanubrutinib, leading to their regulatory approvals in CLL.
In 2014 she was the recipient of two awards from DFCI, the Clinical Innovation Award and the George Canellos Award. She has a worldwide reputation as a CLL expert having made the Highly Cited Researchers list by Clarivate.
